iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20.

The drug, which is iX Biopharma’s second treatment for male erectile dysfunction after Wafesil, has been designed as a novel small capsule, which sets it apart from existing alternatives which are typically delivered in tablet form.

Silcap is the first capsule sildenafil product to obtain marketing approval in Singapore.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook